IGCIGC Pharma, Inc.vs its industry peers
A metric-by-metric comparison of IGC Pharma, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IGC본 종목 | $25M#10 | — | 4.1x#9 | 19.7x#6 | -5.5%#6 | 45.2%#5 | -585.8%#4 | -116.4%#6 | -123.1%#5 | 3#4 | -28.1%#6 | — |
| MIRA | $29M#3 | — | 3.1x#7 | — | — | -33.0%#13 | — | -111.7%#5 | — | — | -56.7%#9 | — |
| ABVC | $28M#4 | — | 2.6x#6 | 94.9x#9 | 48.0%#4 | -61.3%#14 | -2416.0%#7 | -73.4%#3 | -65.9%#3 | — | -66.1%#13 | — |
| KYNB | $27M#5 | 0.2x#3 | — | 4.2x#3 | -78.3%#9 | 485.6%#1 | -712.7%#6 | — | — | — | -3.2%#4 | — |
| ACTU | $27M#6 | — | 7.2x#12 | — | — | 18.5%#7 | — | -587.4%#12 | — | — | -83.8%#15 | — |
| SER | $33M#2 | — | — | 250.3x#10 | 132.1%#2 | -72.2%#16 | -18478.5%#10 | — | — | 5#1 | -58.2%#11 | — |
| CRVO | $26M#8 | 0.0x#1 | 2.5x#5 | 6.5x#4 | -58.9%#7 | -65.6%#15 | -706.2%#5 | -254.1%#10 | -1038.7%#7 | — | -69.7%#14 | — |
| ATNM | $26M#9 | — | 11.1x#13 | 285.1x#11 | — | 11.4%#9 | -40274.4%#12 | -1470.8%#13 | — | — | -50.6%#8 | — |
| HCWB | $25M#11 | — | 4.3x#10 | 453.2x#12 | -97.9%#10 | 73.5%#3 | -24270.7%#11 | -138.1%#7 | -118.5%#4 | 3#4 | -85.2%#16 | — |
| BRNS | $25M#12 | — | 0.4x#1 | — | -100.0%#11 | -8.8%#11 | — | -100.0%#4 | -10079.3%#8 | — | -57.1%#10 | — |
| AYTU | $24M#13 | — | 0.7x#2 | 0.4x#1 | 1.8%#5 | 14.4%#8 | -11.8%#1 | -38.6%#2 | -41.4%#2 | 4#3 | -14.3%#5 | — |
| TXMD | $24M#14 | 102.3x#4 | 0.9x#4 | 7.8x#5 | 71.6%#3 | 73.9%#2 | -145.3%#2 | -2.1%#1 | -3.8%#1 | 5#1 | 71.8%#1 | — |
| BTAI | $27M#7 | — | — | 41.4x#7 | -71.7%#8 | -17.3%#12 | -7860.0%#9 | — | — | — | -65.8%#12 | — |
| RNTX | $66M#1 | — | 5.7x#11 | — | — | 20.7%#6 | — | -430.5%#11 | — | — | -32.6%#7 | — |
| NXTC | $21M#15 | — | 0.8x#3 | 0.9x#2 | 252.6%#1 | -0.3%#10 | -257.5%#3 | -209.0%#9 | -406.1%#6 | — | 15.1%#3 | — |
| ALLR | $21M#16 | 0.0x#2 | 3.1x#8 | 66.1x#8 | — | 54.2%#4 | -3939.1%#8 | -162.3%#8 | — | — | 31.7%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-08-05.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice